Art

J-GLOBAL ID：202302267174938890   Reference number：23A1998310

Leveraging a disulfidptosis-based signature to improve the survival and drug sensitivity of bladder cancer patients

膀胱癌患者の生存と薬剤感受性を改善するためのジスルフィドトーシスに基づくシグネチャーの利用【JST・京大機械翻訳】

Author (5)： Chen Hualin (Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China) ,  Yang Wenjie (Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China) ,  Li Yingjie (Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China) ,  Ma Lin (Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China) ,  Ji Zhigang (Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China)
Material： Frontiers in Immunology (Web)
Volume： 14  Page： 1198878  Publication year： 2023 
JST Material Number： U7074A  ISSN： 1664-3224  Document type： Article
Article type： 原著論文  Country of issue： Switzerland (CHE)  Language： ENGLISH (EN)

Abstract/Point： Background: Disulfidptosis is ...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=23A1998310&from=J-GLOBAL&jstjournalNo=U7074A") }}

Thesaurus term： gene ,  inflammation ,  tumor ,  mutation ,  carcinogenesis ,  phenotype ,  clustering ,  cell proliferation ,  cluster ,  survival ratio ,  prognosis ,  *bladder tumor ,  neoplasm staging ,  *drug sensitivity ,  immunohistochemistry
Semi thesaurus term： 腫瘍進行 , 【Automatic Indexing@JST】

Author keywords (7)： disulfidptosis ,  bladder cancer ,  molecular clusters ,  tumor immune microenvironment ,  prognostic model ,  POU5F1 ,  CTSE

JST classification (2)： Tumors(=neoplasms)of digestive system  (GH04000D) ,  Chemistry,biochemistry and pathology of tumors(=neoplasms)  (GE02030N)

Reference (43)：

• Chen H, Yang W, Xue X, Li Y, Jin Z, Ji Z. Neoadjuvant immunotherapy and chemoimmunotherapy for stage II-III muscle invasive bladder cancer. Front Immunol (2022) 13:986359. doi: doi: 10.3389/fimmu.2022.986359
• Lenis AT, Lec PM, Chamie K, Mshs MD. Bladder cancer: a review. Jama. (2020) 324(19):1980-91. doi: doi: 10.1001/jama.2020.17598
• Malmström PU, Rintala E, Wahlqvist R, Hellström P, Hellsten S, Hannisdal E. Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic cystectomy trial i. the Nordic cooperative bladder cancer study group. J Urol. (1996) 155(6):1903-6. doi: doi: 10.1016/S0022-5347(01)66042-7
• Chen X, Zhang J, Ruan W, Huang M, Wang C, Wang H, et al. Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancer. J Clin Invest. (2020) 130(12):6278-89. doi: doi: 10.1172/JCI139597
• Liu X, Nie L, Zhang Y, Yan Y, Wang C, Colic M, et al. Actin cytoskeleton vulnerability to disulfide stress mediates disulfidptosis. Nat Cell Biol (2023) 25(3):404-414. doi: doi: 10.1038/s41556-023-01091-2

Terms in the title (5)： 膀胱 ,  癌患者 ,  生存 ,  薬剤感受性 ,  シグネチャー